Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIONIKK: Nivolumab and Ipilimumab or VEGFR TKI in Metastatic Kidney Cancer
NCT02960906Phase 2Completed
- Sponsor
- ARTIC
- Start
- May 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in clear cell renal cell carcinoma (ccRCC) (8 arms), sponsored by ARTIC. Primary endpoint: Objective Response Rate at 54 months. Started May 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02960906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960906.